NZ601167A - Treatment of cardiac conditions - Google Patents

Treatment of cardiac conditions

Info

Publication number
NZ601167A
NZ601167A NZ601167A NZ60116711A NZ601167A NZ 601167 A NZ601167 A NZ 601167A NZ 601167 A NZ601167 A NZ 601167A NZ 60116711 A NZ60116711 A NZ 60116711A NZ 601167 A NZ601167 A NZ 601167A
Authority
NZ
New Zealand
Prior art keywords
treatment
cardiac conditions
heart
glp
glucagon
Prior art date
Application number
NZ601167A
Other languages
English (en)
Inventor
Bjarne Due Larsen
Rie Schultz Hansen
Keld Fosgerau
Lene Axelsen
Jorgen Soberg Petersen
Henrik Duelund Pedersen
Marie Skovgaard
Ditte Riber
Eddi Meier
Anne Louise Kjoelbye
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43928934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ601167(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of NZ601167A publication Critical patent/NZ601167A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NZ601167A 2010-01-20 2011-01-20 Treatment of cardiac conditions NZ601167A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29665710P 2010-01-20 2010-01-20
PCT/DK2011/050018 WO2011088837A1 (en) 2010-01-20 2011-01-20 Treatment of cardiac conditions

Publications (1)

Publication Number Publication Date
NZ601167A true NZ601167A (en) 2014-12-24

Family

ID=43928934

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ601167A NZ601167A (en) 2010-01-20 2011-01-20 Treatment of cardiac conditions

Country Status (15)

Country Link
US (1) US20130157953A1 (enExample)
EP (1) EP2525809B1 (enExample)
JP (2) JP2013517307A (enExample)
KR (1) KR20120128129A (enExample)
CN (1) CN102892425A (enExample)
AU (1) AU2011206979B2 (enExample)
BR (1) BR112012018104A2 (enExample)
CA (1) CA2786934A1 (enExample)
CL (1) CL2012002037A1 (enExample)
EA (1) EA026384B1 (enExample)
IL (1) IL220876A0 (enExample)
MX (1) MX342409B (enExample)
NZ (1) NZ601167A (enExample)
PH (1) PH12012501494A1 (enExample)
WO (1) WO2011088837A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011006314A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
AU2008365559B2 (en) 2008-12-15 2016-02-25 Zealand Pharma A/S Glucagon analogues
KR20150116912A (ko) 2008-12-15 2015-10-16 질랜드 파마 에이/에스 글루카곤 유사체
BRPI0823379A2 (pt) 2008-12-15 2015-07-14 Zealand Pharma As Análogos de glucagon
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
SG184988A1 (en) 2010-04-27 2012-11-29 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
UY33462A (es) * 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
SG186764A1 (en) * 2010-06-24 2013-02-28 Zealand Pharma As Glucagon analogues
AU2012331053A1 (en) 2011-11-03 2014-05-29 Zealand Pharma A/S GLP-1 receptor agonist peptide gastrin conjugates
PE20142113A1 (es) * 2011-12-23 2014-12-03 Zealand Pharma As Analogos de glucagon
TWI689515B (zh) 2012-05-03 2020-04-01 丹麥商西蘭製藥公司 Ｇｉｐ-ｇｌｐ-１雙重促效劑化合物及方法
KR102129235B1 (ko) 2012-07-23 2020-07-06 질랜드 파마 에이/에스 글루카곤 유사체
TWI608013B (zh) * 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2014049610A2 (en) * 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013347975B2 (en) * 2012-11-20 2018-07-26 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
EP2935318A1 (en) * 2012-12-19 2015-10-28 Novo Nordisk A/S Novel glp-1 receptor agonists with cholesterol efflux activity
LT2934567T (lt) 2012-12-21 2018-09-10 Sanofi Eksendino-4 dariniai kaip dvigubi glp1/gip arba trigubi glp1/gip/gliukagono agonistai
MX362275B (es) 2013-04-18 2019-01-10 Novo Nordisk As Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
US9896495B2 (en) * 2013-10-17 2018-02-20 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
EA035688B1 (ru) * 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
WO2015067715A2 (en) * 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
CN103724424B (zh) * 2013-12-27 2015-05-27 浙江省农业科学院 一种mPEG-SPA-pGLP-2复合物及其制备方法和应用
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9988430B2 (en) 2014-10-10 2018-06-05 Novo Nordisk A/S Stable GLP-1 based GLP-1/glucagon receptor co-agonists
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
UA126960C2 (uk) 2014-12-30 2023-03-01 Ханмі Фарм. Ко., Лтд. Похідна глюкагону
KR102418477B1 (ko) * 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
TWI707867B (zh) 2015-04-16 2020-10-21 丹麥商西蘭製藥公司 醯化之昇糖素類似物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
CN108025041A (zh) 2015-06-30 2018-05-11 韩美药品株式会社 胰高血糖素衍生物和包含其长效缀合物的组合物
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
DK3398961T3 (da) 2015-12-31 2022-08-22 Hanmi Pharm Ind Co Ltd Tredobbelt aktivator, der aktiverer glukagon, glp 1 og gip-receptor
GB2566228A (en) 2016-06-09 2019-03-06 AmideBio LLC Glucagon analogs and methods of use thereof
TWI757305B (zh) 2016-06-29 2022-03-11 南韓商韓美藥品股份有限公司 升糖素衍生物、其接合物、及包含其之組成物、及其醫療用途
WO2018104561A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
CN109836503B (zh) * 2017-11-24 2022-09-16 浙江道尔生物科技有限公司 一种治疗代谢疾病的多重活性蛋白
CN109836488B (zh) * 2017-11-24 2022-08-23 浙江道尔生物科技有限公司 一种治疗代谢疾病的胰高血糖素类似物
TWI809515B (zh) * 2017-12-21 2023-07-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CA3086918A1 (en) 2018-01-03 2019-07-11 Mederis Diabetes, Llc Improved peptide pharmaceuticals for treatment of nash and other disorders
WO2021083306A1 (zh) * 2019-10-31 2021-05-06 东莞市东阳光生物药研发有限公司 Glp-1/gcg双受体激动剂多肽
EP3842060A1 (en) * 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled lactam co-agonists of the glucagon and glp-1 receptors
CN113621045A (zh) * 2020-05-09 2021-11-09 天津药物研究院有限公司 具有双受体激动作用的多肽衍生物及其用途
US12171806B2 (en) 2021-09-28 2024-12-24 Spitfire Pharma Llc Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4677095B2 (ja) * 1998-02-13 2011-04-27 アミリン・ファーマシューティカルズ，インコーポレイテッド エキセンジンおよびｇｌｐ−１の変力および利尿効果
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
WO2002034285A2 (en) * 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7192922B2 (en) * 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
US7928058B2 (en) 2006-02-22 2011-04-19 Merck Sharp & Dohme Corp. Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US8454971B2 (en) 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
DK2158214T3 (da) * 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
EP2676673B1 (en) 2008-06-17 2016-11-16 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2009155257A1 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
WO2010107487A2 (en) * 2009-03-18 2010-09-23 Wu Nian Lipid-drug conjugates for drug delivery
TWI608013B (zh) * 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物

Also Published As

Publication number Publication date
EP2525809B1 (en) 2016-08-03
EA201290540A1 (ru) 2013-03-29
JP2013517307A (ja) 2013-05-16
EA026384B1 (ru) 2017-04-28
JP6200025B2 (ja) 2017-09-20
AU2011206979A1 (en) 2012-08-02
CA2786934A1 (en) 2011-07-28
BR112012018104A2 (pt) 2017-10-17
IL220876A0 (en) 2012-09-24
JP2016138127A (ja) 2016-08-04
CN102892425A (zh) 2013-01-23
CL2012002037A1 (es) 2012-09-07
EP2525809A1 (en) 2012-11-28
PH12012501494A1 (en) 2012-10-22
MX2012008440A (es) 2012-08-15
KR20120128129A (ko) 2012-11-26
WO2011088837A1 (en) 2011-07-28
AU2011206979B2 (en) 2015-09-10
MX342409B (es) 2016-09-28
US20130157953A1 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
NZ601167A (en) Treatment of cardiac conditions
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
PL2453923T3 (pl) Niekowalencyjne dostarczanie aktywnych czynników przez barierę krew-mózg przy udziale peptydów
AP2012006339A0 (en) Methods of administering pirfenidone therapy.
PL3626208T3 (pl) Zastawka protetyczna serca z cewnikiem wprowadzającym
IL259475A (en) Combined therapy for the treatment of diabetes
IL232251B (en) Pharmaceutical combination for use in the treatment of type 2 diabetes patients
IL221744A (en) Use of a combination of compounds to prepare a drug to treat Parkinson's disease
IL217901B (en) Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases
ZA201107215B (en) Therapeutic agents for the treatment of diseases associated with undersired cell proliferation
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
ZA201208646B (en) Pharmaceutical combination for the treatment of pain
IL260078B (en) Therapy used to treat Gaucher disease
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
EP2563395A4 (en) TREATMENT WITH ANTI-S1P ANTIBODY OF PATIENTS WITH OCULAR DISEASES
IL208751A0 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
MX2013006564A (es) Uso de dronedarona para la preparacion de un farmaco para uso en la gestion del riesgo de daño hpatico.
PL2538918T3 (pl) Cytocholina do leczenia jaskry
IL218230B (en) Use of lapatinib or an acceptable pharmaceutical salt or preparation thereof for the preparation of a drug for the treatment of cancer
PL2556806T3 (pl) Wszczepialna proteza medyczna
SG10201510484YA (en) A drug eluting patch for the treatment of localized tissue disease or defect
ZA201400488B (en) Compounds for the treatment of cancers associated with human papillomavirus
ZA201306759B (en) Compounds for use in imaging,diagnosing and/or treatment of diseases of the central nervous system
PT2456445E (pt) Agente para o tratamento de condições da pele

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 20 JAN 2018 BY HENRY HUGHES IP LIMITED

Effective date: 20150424

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JAN 2019 BY MEWBURN ELLIS LLP

Effective date: 20171214

LAPS Patent lapsed